Latest & greatest articles for gemfibrozil

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on gemfibrozil or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on gemfibrozil and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for gemfibrozil

1. Gemfibrozil

Gemfibrozil Top results for gemfibrozil - Trip Database or use your Google+ account Liberating the literature ALL of these words: Title only Anywhere in the document ANY of these words: Title only Anywhere in the document This EXACT phrase: Title only Anywhere in the document EXCLUDING words: Title only Anywhere in the document Timeframe: to: Combine searches by placing the search numbers in the top search box and pressing the search button. An example search might look like (#1 or #2) and (#3 (...) or #4) Loading history... Population: Intervention: Comparison: Outcome: Population: Intervention: Latest & greatest articles for gemfibrozil The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence

2018 Trip Latest and Greatest

2. Post-prandial effects of gemfibrozil vs simvastatin in hypercholesterolemic subjects with borderline hypertriglyceridemia. (Abstract)

Post-prandial effects of gemfibrozil vs simvastatin in hypercholesterolemic subjects with borderline hypertriglyceridemia. Impaired triglyceride-rich lipoprotein metabolism is most probably related to an enhanced cardiovascular risk, and may be associated with a pro-coagulant state. A double-blind, randomized study was undertaken to evaluate two widely utilized hypolipidemic drugs in the post-prandial phase and their impact on lipid, coagulation and fibrinolytic parameters.Thirty middle-aged (...) men selected according to their low density lipoprotein-cholesterol (LDL-C) > or = 160 and < or = 240 mg/dl and borderline hypertriglyceridemia (110-220 mg/dl) after at least one month of a lipid-lowering diet received gemfibrozil (600 mg bid) or simvastatin (20 mg qd) and the corresponding placebo. On enrollment and after 2 months of drug treatment, they were tested with a standard oral fat load (OFL) (35 g fat/m2 body surface). On both occasions plasma total-cholesterol, LDL-C, HDL-C

1999 Nutrition, metabolism, and cardiovascular diseases : NMCD Controlled trial quality: uncertain

3. Relation of gemfibrozil treatment and lipid levels with major coronary events: VA-HIT: a randomized controlled trial. (Abstract)

Relation of gemfibrozil treatment and lipid levels with major coronary events: VA-HIT: a randomized controlled trial. A low plasma level of high-density lipoprotein cholesterol (HDL-C) is a major risk factor for coronary heart disease (CHD). A secondary prevention study, the Veterans Affairs High-Density Lipoprotein Intervention Trial (VA-HIT), demonstrated that CHD events were significantly reduced during a median follow-up of 5.1 years by treating patients with the fibric acid derivative (...) gemfibrozil when the predominant lipid abnormality was low HDL-C.To determine if the reduction in major CHD events with gemfibrozil in VA-HIT could be attributed to changes in major plasma lipid levels.Multicenter, randomized, double-blind, placebo-controlled trial conducted from September 1991 to August 1998.The Department of Veterans Affairs Cooperative Studies Program, in which 20 VA medical centers were participating sites.A total of 2531 men with a history of CHD who had low HDL-C levels (mean, 32 mg

2001 JAMA Controlled trial quality: predicted high

4. Clopidogrel and Gemfibrozil Strongly Inhibit the CYP2C8-dependent Formation of 3-Hydroxydesloratadine and Increase Desloratadine Exposure In Humans. Full Text available with Trip Pro

Clopidogrel and Gemfibrozil Strongly Inhibit the CYP2C8-dependent Formation of 3-Hydroxydesloratadine and Increase Desloratadine Exposure In Humans. A recent in vitro study suggested that CYP2C8 is essential in the metabolism of desloratadine, an H1 receptor antagonist. If the proposed biotransformation mechanism takes place in vivo in humans, desloratadine could serve as a selective CYP2C8 probe substrate in drug-drug interaction studies. Glucuronide metabolites of clopidogrel and gemfibrozil (...) act as time-dependent inhibitors of CYP2C8, but they have not been compared clinically. We conducted a randomized crossover study in 11 healthy subjects to characterize the involvement of CYP2C8 in desloratadine metabolism and to compare the CYP2C8 inhibitory strength of clopidogrel (300 and 75 mg on two following days) with that of gemfibrozil (600 mg BID for 5 days). Compared with placebo (control), clopidogrel increased the area under the plasma concentration-time curve (AUC0-∞) and peak plasma

2019 Drug metabolism and disposition: the biological fate of chemicals Controlled trial quality: uncertain

5. Effects of gemfibrozil on lipid and hemostatic factors in CAPD patients. (Abstract)

Effects of gemfibrozil on lipid and hemostatic factors in CAPD patients. 10433170 1999 09 07 2013 11 21 0896-8608 19 3 1999 May-Jun Peritoneal dialysis international : journal of the International Society for Peritoneal Dialysis Perit Dial Int Effects of gemfibrozil on lipid and hemostatic factors in CAPD patients. 280-3 Lee M S MS Department of Internal Medicine, University of Ulsan, Seoul, Korea. Kim S M SM Kim S B SB Lee S K SK Park J S JS Yang W S WS eng Clinical Trial Journal Article (...) Randomized Controlled Trial Research Support, Non-U.S. Gov't Canada Perit Dial Int 8904033 0896-8608 0 Blood Coagulation Factors 0 Hypolipidemic Agents 0 Lipids 0 von Willebrand Factor 9001-25-6 Factor VII 9001-32-5 Fibrinogen Q8X02027X3 Gemfibrozil IM Adult Aged Blood Coagulation Factors analysis Factor VII analysis Female Fibrinogen analysis Gemfibrozil therapeutic use Humans Hypertriglyceridemia blood drug therapy Hypolipidemic Agents therapeutic use Lipids blood Male Middle Aged Peritoneal Dialysis

1999 Peritoneal dialysis international : journal of the International Society for Peritoneal Dialysis Controlled trial quality: uncertain

6. A controlled trial of gemfibrozil in the treatment of patients with nonalcoholic steatohepatitis. (Abstract)

A controlled trial of gemfibrozil in the treatment of patients with nonalcoholic steatohepatitis. 10453959 1999 09 15 2013 11 21 0168-8278 31 2 1999 Aug Journal of hepatology J. Hepatol. A controlled trial of gemfibrozil in the treatment of patients with nonalcoholic steatohepatitis. 384 Basaranoglu M M Acbay O O Sonsuz A A eng Clinical Trial Comment Letter Randomized Controlled Trial Netherlands J Hepatol 8503886 0168-8278 0 Hypolipidemic Agents 0 Triglycerides Q8X02027X3 Gemfibrozil IM J (...) Hepatol. 1998 Sep;29(3):495-501 9765002 Adult Female Gemfibrozil therapeutic use Hepatitis, Chronic drug therapy metabolism Humans Hypolipidemic Agents therapeutic use Liver enzymology Liver Function Tests Male Middle Aged Triglycerides blood metabolism 1999 8 24 1999 8 24 0 1 1999 8 24 0 0 ppublish 10453959 S0168-8278(99)80243-8

1999 Journal of Hepatology Controlled trial quality: uncertain

7. Vitamin C may have similar beneficial effects to Gemfibrozil on serum high-density lipoprotein-cholesterol in type 2 diabetic patients. Full Text available with Trip Pro

Vitamin C may have similar beneficial effects to Gemfibrozil on serum high-density lipoprotein-cholesterol in type 2 diabetic patients. Type 2 diabetes mellitus (DM-T2) is commonly associated with increased triglycerides (TG), low-density lipoprotein cholesterol (LDL-C) and low high-density lipoprotein cholesterol (HDL-C) levels. Fibrates like gemfibrozil are frequently used in diabetic patients to decrease TG and increase HDL-C levels. We compared the efficacy of Vitamin C, an antioxidant (...) vitamin, with gemfibrozil on serum HDL-C in diabetic patients.Type 2 diabetic patients, referred to our out-patient clinic were randomly divided into three groups. After 1 month of lifestyle and diet modifications, groups A, B, and C were prescribed 1000 mg Vitamin C, 600 mg gemfibrozil and combination of both, respectively. Before the study initiation and after 6(th) week of drug prescription, the blood samples were taken and analyzed for total cholesterol (Total-C), HDL-C, TG, fasting blood sugar

2014 Journal of research in pharmacy practice Controlled trial quality: uncertain

8. Decreased cyclosporine levels during gemfibrozil treatment of hyperlipidemia after kidney transplantation. Full Text available with Trip Pro

Decreased cyclosporine levels during gemfibrozil treatment of hyperlipidemia after kidney transplantation. 8852502 1996 12 11 2018 02 15 1660-8151 72 3 1996 Nephron Nephron Decreased cyclosporine levels during gemfibrozil treatment of hyperlipidemia after kidney transplantation. 483 Fehrman-Ekholm I I Jogestrand T T Angelin B B eng Clinical Trial Letter Randomized Controlled Trial Switzerland Nephron 0331777 1660-8151 0 Hypolipidemic Agents 0 Immunosuppressive Agents 83HN0GTJ6D Cyclosporine (...) Q8X02027X3 Gemfibrozil IM Cyclosporine blood pharmacology Gemfibrozil pharmacology Humans Hyperlipidemias drug therapy Hypolipidemic Agents pharmacology Immunosuppressive Agents blood pharmacology Kidney Transplantation 1996 1 1 1996 1 1 0 1 1996 1 1 0 0 ppublish 8852502 10.1159/000188918

1996 Nephron Controlled trial quality: uncertain

9. Further evidence of favorable effects of gemfibrozil on the lipid profile in renal allograft recipients. Full Text available with Trip Pro

Further evidence of favorable effects of gemfibrozil on the lipid profile in renal allograft recipients. 8832618 1996 12 26 2018 02 15 1660-8151 73 3 1996 Nephron Nephron Further evidence of favorable effects of gemfibrozil on the lipid profile in renal allograft recipients. 491-2 Ok E E Kursat S S Alev M M Tobu M M Tokat Y Y Akcicek F F Hoscoskun C C Basci A A eng Clinical Trial Controlled Clinical Trial Letter Randomized Controlled Trial Switzerland Nephron 0331777 1660-8151 0 Hypolipidemic (...) Agents 0 Lipids Q8X02027X3 Gemfibrozil IM Adult Female Gemfibrozil therapeutic use Humans Hypolipidemic Agents therapeutic use Kidney Transplantation physiology Lipids blood Male 1996 1 1 1996 1 1 0 1 1996 1 1 0 0 ppublish 8832618 10.1159/000189121

1996 Nephron Controlled trial quality: uncertain

10. The hypolipidaemic effect of gemfibrozil (CI-719) in laboratory animals. Full Text available with Trip Pro

The hypolipidaemic effect of gemfibrozil (CI-719) in laboratory animals. 828263 1977 04 25 2018 11 13 0035-9157 69 Suppl 2 1976 Proceedings of the Royal Society of Medicine Proc. R. Soc. Med. The hypolipidaemic effect of gemfibrozil (CI-719) in laboratory animals. 6-10 Rodney G G Uhlendorf P P Maxwell R E RE eng Journal Article England Proc R Soc Med 7505890 0035-9157 0 Hypolipidemic Agents 0 Lipids 0 Triglycerides 0 Valerates 0 Xylenes 97C5T2UQ7J Cholesterol HPN91K7FU3 Clofibrate IM Animals

1976 Proceedings of the Royal Society of Medicine

11. Toxicological studies on gemfibrozil. Full Text available with Trip Pro

Toxicological studies on gemfibrozil. 828262 1977 04 25 2018 11 13 0035-9157 69 Suppl 2 1976 Proceedings of the Royal Society of Medicine Proc. R. Soc. Med. Toxicological studies on gemfibrozil. 15-23 Kurtz S M SM Fitzgerald J E JE Fisken R A RA Schardein J L JL Reutner T H TH Lucas J A JA eng Journal Article England Proc R Soc Med 7505890 0035-9157 0 Hypolipidemic Agents 0 Teratogens 0 Valerates 0 Xylenes IM Animals Dogs Female Fetus drug effects Haplorhini Hypolipidemic Agents toxicity Lethal

1976 Proceedings of the Royal Society of Medicine

12. Toleration and bioavailability of gemfibrozil in healthy men. Full Text available with Trip Pro

Toleration and bioavailability of gemfibrozil in healthy men. 798193 1977 04 25 2013 11 21 0035-9157 69 Suppl 2 1976 Proceedings of the Royal Society of Medicine Proc. R. Soc. Med. Toleration and bioavailability of gemfibrozil in healthy men. 24-7 Smith T C TC eng Clinical Trial Journal Article England Proc R Soc Med 7505890 0035-9157 0 Hypolipidemic Agents 0 Triglycerides 0 Valerates 0 Xylenes 97C5T2UQ7J Cholesterol IM Biological Availability Chemical Phenomena Chemistry Cholesterol blood

1976 Proceedings of the Royal Society of Medicine

13. Preliminary observations on the effect of gemfibrozil on the excretion of faecal bile acids. Full Text available with Trip Pro

Preliminary observations on the effect of gemfibrozil on the excretion of faecal bile acids. 1019150 1977 04 25 2018 11 13 0035-9157 69 Suppl 2 1976 Proceedings of the Royal Society of Medicine Proc. R. Soc. Med. Preliminary observations on the effect of gemfibrozil on the excretion of faecal bile acids. 112-4 Baird I M IM Lewis B B Hill J M JM eng Journal Article England Proc R Soc Med 7505890 0035-9157 0 Bile Acids and Salts 0 Hypolipidemic Agents 0 Triglycerides 0 Valerates 0 Xylenes

1976 Proceedings of the Royal Society of Medicine

14. Gemfibrozil: a new lipid lowering agent. Open forum. Full Text available with Trip Pro

Gemfibrozil: a new lipid lowering agent. Open forum. 1019151 1977 04 25 2010 11 18 0035-9157 69 Suppl 2 1976 Proceedings of the Royal Society of Medicine Proc. R. Soc. Med. Gemfibrozil: a new lipid lowering agent. Open forum. 115-20 eng Journal Article England Proc R Soc Med 7505890 0035-9157 0 Hypolipidemic Agents 0 Lipoproteins 0 Triglycerides 0 Valerates 0 Xylenes IM Humans Hypolipidemic Agents pharmacology Lipoproteins blood Triglycerides blood Valerates pharmacology Xylenes pharmacology

1976 Proceedings of the Royal Society of Medicine

15. Gemfibrozil: effect on serum lipids, lipoproteins, postheparin plasma lipase activities and glucose tolerance in primary hypertriglyceridaemia. Full Text available with Trip Pro

Gemfibrozil: effect on serum lipids, lipoproteins, postheparin plasma lipase activities and glucose tolerance in primary hypertriglyceridaemia. The hypolipidaemic effect of a new drug, gemfibrozil (CI-719), was studied for 20 weeks in 20 patients with primary type IIb, III, IV or V hyperlipoproteinaemia. Baseline recordings of serum cholesterol (9.1 mmol/l), triglyceride (3.79 mmol/l) and ultra-centrifugally isolated lipoproteins were obtained during a six-week pretreatment period with stable (...) diet and body weight. With 800 mg of gemfibrozil per day given in two divided doses, the mean serum triglyceride and cholesterol levels were decreased by 44.6% and 10.5% respectively, during 20 treatment weeks. Only 2 patients were completely resistant to the hypolipidaemic action of the drug. Serum triglyceride was brought down to normal levels in 9 subjects. After 12 weeks of treatment the mean VLDL-triglyceride, VLDL-cholesterol, and LDL-triglyceride were reduced by 48.5%, 57.6%, and 22.7

1976 Proceedings of the Royal Society of Medicine

16. The evaluation of lipoprotein changes during gemfibrozil treatment. Full Text available with Trip Pro

The evaluation of lipoprotein changes during gemfibrozil treatment. During treatment with gemfibrozil, 1200 mg daily, total serum triglyceride levels were reduced in 7 of the 11 patients, owing chiefly to a fall in VLDL triglyceride levels. Total serum cholesterol responded variably, falling in a majority of patients with hypercholesterolaemia. High density lipoprotein cholesterol rose during treatment in patients who had either hypertriglyceridaemia or hypercholesterolaemia.

1976 Proceedings of the Royal Society of Medicine

17. Effect of gemfibrozil on lipolysis in dogs in vivo. Full Text available with Trip Pro

Effect of gemfibrozil on lipolysis in dogs in vivo. 1019148 1977 04 25 2013 11 21 0035-9157 69 Suppl 2 1976 Proceedings of the Royal Society of Medicine Proc. R. Soc. Med. Effect of gemfibrozil on lipolysis in dogs in vivo. 107-8 Riemersma R A RA Oliver M F MF eng Journal Article England Proc R Soc Med 7505890 0035-9157 0 Fatty Acids, Nonesterified 0 Hypolipidemic Agents 0 Valerates 0 Xylenes PDC6A3C0OX Glycerol IM Animals Depression, Chemical Dogs Fatty Acids, Nonesterified blood Glycerol

1976 Proceedings of the Royal Society of Medicine

18. Extrinsic factors affecting the response to gemfibrozil. Full Text available with Trip Pro

Extrinsic factors affecting the response to gemfibrozil. 1019154 1977 04 25 2018 11 13 0035-9157 69 Suppl 2 1976 Proceedings of the Royal Society of Medicine Proc. R. Soc. Med. Extrinsic factors affecting the response to gemfibrozil. 53-7 Huunan-Seppälä A A Manninen V V Burton R R Eisalo A A eng Journal Article England Proc R Soc Med 7505890 0035-9157 0 Hypolipidemic Agents 0 Triglycerides 0 Valerates 0 Xylenes 97C5T2UQ7J Cholesterol E1UOL152H7 Iron IM Adult Age Factors Cholesterol blood Diet

1976 Proceedings of the Royal Society of Medicine

19. Gemfibrozil--a new lipid lowering agent. Full Text available with Trip Pro

Gemfibrozil--a new lipid lowering agent. 798192 1977 04 25 2013 11 21 0035-9157 69 Suppl 2 1976 Proceedings of the Royal Society of Medicine Proc. R. Soc. Med. Gemfibrozil--a new lipid lowering agent. 1-2 Hodges R M RM eng Historical Article Journal Article England Proc R Soc Med 7505890 0035-9157 0 Hypolipidemic Agents 0 Valerates 0 Xylenes HPN91K7FU3 Clofibrate IM Q Clofibrate analogs & derivatives Europe History, 20th Century Humans Hypolipidemic Agents history United States Valerates

1976 Proceedings of the Royal Society of Medicine

20. The use of gemfibrozil in the treatment of primary hyperlipoproteinaemia. Preliminary report. Full Text available with Trip Pro

The use of gemfibrozil in the treatment of primary hyperlipoproteinaemia. Preliminary report. 798200 1977 04 25 2013 11 21 0035-9157 69 Suppl 2 1976 Proceedings of the Royal Society of Medicine Proc. R. Soc. Med. The use of gemfibrozil in the treatment of primary hyperlipoproteinaemia. Preliminary report. 78-9 Honorato J J Masso R M RM Purroy A A eng Clinical Trial Journal Article England Proc R Soc Med 7505890 0035-9157 0 Hypolipidemic Agents 0 Lipoproteins 0 Triglycerides 0 Valerates 0

1976 Proceedings of the Royal Society of Medicine